Conference
A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.
Abstract
2599
Background: Second mitochondria-derived activator of caspase (SMAC) mimetics regulate apoptosis and modulate NFκB signaling which drives the expression of genes involved in immune and inflammatory responses. In patient (pt) tumors, Debio 1143 increased PD-1/PD-L1 expression and tumor infiltrating lymphocytes. In pre-clinical models, it synergizes in vitro and in vivo with PD1/PD-L1 checkpoint inhibitors (CPIs). Methods: …
Authors
Juergens RA; Chu QS; Renouf DJ; Laurie SA; Purcea D; McWhirter E; Arndt D; Gelmon KA; Hilton J; Gavillet B
Volume
37
Pagination
pp. 2599-2599
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2019
DOI
10.1200/jco.2019.37.15_suppl.2599
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X